Effectiveness of training general practitioners to improve the implementation of brief stop-smoking advice in German primary care: study protocol of a pragmatic, 2-arm cluster randomised controlled trial (the ABCII trial).


Journal

BMC family practice
ISSN: 1471-2296
Titre abrégé: BMC Fam Pract
Pays: England
ID NLM: 100967792

Informations de publication

Date de publication:
27 07 2019
Historique:
received: 08 11 2018
accepted: 27 06 2019
entrez: 29 7 2019
pubmed: 29 7 2019
medline: 9 4 2020
Statut: epublish

Résumé

The German clinical guideline on tobacco addiction recommends that general practitioners (GPs) provide brief stop-smoking advice to their patients according to the "5A" or the much briefer "ABC" method, but its implementation is insufficient. A lack of training is one barrier for GPs to provide such advice. Moreover, the respective effectiveness of a 5A or ABC training regarding subsequent delivery of stop-smoking advice has not been investigated. We developed a training for GPs according to both methods, and conducted a pilot study with process evaluation to optimize the trainings according to the needs of GPs. This study aims at evaluating the effectiveness of both trainings. A pragmatic 2-arm cluster randomised controlled trial with a pre-post data collection will be conducted in 48 GP practices in North Rhine-Westphalia (Germany). GPs will be randomised to receive a 3.5-h-training in delivering either 5A or ABC, including peer coaching and intensive role plays with professional actors. The patient-reported primary outcome (receipt of GP advice to quit: yes/no) and secondary outcomes (recommendation rates of smoking cessation treatments, group comparison (5A versus ABC): receipt of GP advice to quit) will be collected in smoking patients routinely consulting their GP within 4 weeks prior, and 4 weeks following the training. Additional secondary outcomes will be collected at 4, 12 and 26 weeks following the consultation: use of cessation treatments during the last quit attempt (if so) since the GP consultation, and point-prevalence abstinence rates. The primary data analysis will be conducted using a mixed-effects logistic regression model with random effects for the cluster variable. If the training increases the rates of delivery of stop-smoking advice, it would offer a low-threshold strategy for the guideline implementation in German primary care. Should one method prove superior, a more specific guideline recommendation can be proposed. German Clinical Trials Register (DRKS00012786); registered on 22th August 2017, prior to the first patient in.

Sections du résumé

BACKGROUND
The German clinical guideline on tobacco addiction recommends that general practitioners (GPs) provide brief stop-smoking advice to their patients according to the "5A" or the much briefer "ABC" method, but its implementation is insufficient. A lack of training is one barrier for GPs to provide such advice. Moreover, the respective effectiveness of a 5A or ABC training regarding subsequent delivery of stop-smoking advice has not been investigated. We developed a training for GPs according to both methods, and conducted a pilot study with process evaluation to optimize the trainings according to the needs of GPs. This study aims at evaluating the effectiveness of both trainings.
METHODS
A pragmatic 2-arm cluster randomised controlled trial with a pre-post data collection will be conducted in 48 GP practices in North Rhine-Westphalia (Germany). GPs will be randomised to receive a 3.5-h-training in delivering either 5A or ABC, including peer coaching and intensive role plays with professional actors. The patient-reported primary outcome (receipt of GP advice to quit: yes/no) and secondary outcomes (recommendation rates of smoking cessation treatments, group comparison (5A versus ABC): receipt of GP advice to quit) will be collected in smoking patients routinely consulting their GP within 4 weeks prior, and 4 weeks following the training. Additional secondary outcomes will be collected at 4, 12 and 26 weeks following the consultation: use of cessation treatments during the last quit attempt (if so) since the GP consultation, and point-prevalence abstinence rates. The primary data analysis will be conducted using a mixed-effects logistic regression model with random effects for the cluster variable.
DISCUSSION
If the training increases the rates of delivery of stop-smoking advice, it would offer a low-threshold strategy for the guideline implementation in German primary care. Should one method prove superior, a more specific guideline recommendation can be proposed.
TRIAL REGISTRATION
German Clinical Trials Register (DRKS00012786); registered on 22th August 2017, prior to the first patient in.

Identifiants

pubmed: 31351460
doi: 10.1186/s12875-019-0986-8
pii: 10.1186/s12875-019-0986-8
pmc: PMC6660716
doi:

Banques de données

DRKS
['DRKS00012786']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107

Références

Eur J Public Health. 2017 Feb 1;27(1):129-134
pubmed: 28177479
Gesundheitswesen. 2016 Nov;78(11):752-758
pubmed: 26158343
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
J Clin Epidemiol. 2015 Jun;68(6):693-7
pubmed: 25450450
Eur J Cardiovasc Prev Rehabil. 2011 Apr;18(2):334-41
pubmed: 21450679
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Ann Behav Med. 2013 Aug;46(1):81-95
pubmed: 23512568
BMC Med Educ. 2010 Mar 31;10:27
pubmed: 20353612
Tob Control. 2008 Jun;17(3):173-6
pubmed: 18522969
Nicotine Tob Res. 2014 Jan;16(1):1-10
pubmed: 23873981
BMJ Open. 2015 Feb 18;5(2):e007166
pubmed: 25694460
PLoS One. 2016 Dec 21;11(12):e0168482
pubmed: 28002498
Addiction. 2015 Mar;110(3):387-8
pubmed: 25678284
Tob Induc Dis. 2017 Nov 2;15:41
pubmed: 29142531
Patient Educ Couns. 2006 Oct;63(1-2):232-8
pubmed: 16531000
J Adv Nurs. 2008 Apr;62(1):107-15
pubmed: 18352969
Eur J Gen Pract. 2013 Jun;19(2):99-105
pubmed: 23514137
Dtsch Arztebl Int. 2018 Apr 6;115(14):235-242
pubmed: 29716687
Addiction. 2017 Dec;112(12):2237-2247
pubmed: 28667826
Tob Control. 2017 Jul;26(4):455-457
pubmed: 27377343
N Engl J Med. 2008 Jun 5;358(23):2468-81
pubmed: 18525043
JAMA Intern Med. 2015 Sep;175(9):1509-16
pubmed: 26076313
BMC Fam Pract. 2013 Jul 30;14:108
pubmed: 23899116
Addiction. 2004 Jan;99(1):29-38
pubmed: 14678060
Addiction. 2011 Mar;106(3):631-8
pubmed: 21134020
Drug Alcohol Depend. 2013 Feb 1;128(1-2):15-9
pubmed: 22943961
Nicotine Tob Res. 2002 May;4(2):149-59
pubmed: 12028847
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
N Engl J Med. 2013 Jan 24;368(4):341-50
pubmed: 23343063
Tob Control. 2007 Feb;16(1):15-21
pubmed: 17297068
Eur J Public Health. 2005 Apr;15(2):140-5
pubmed: 15941758
BMJ. 2006 Feb 25;332(7539):458-60
pubmed: 16443610
Health Educ Behav. 2018 Dec;45(6):888-897
pubmed: 29862845
Nicotine Tob Res. 2018 Nov 15;20(12):1525-1528
pubmed: 29099979
Cochrane Database Syst Rev. 2012 May 16;(5):CD000214
pubmed: 22592671
Addiction. 2015 Sep;110(9):1388-403
pubmed: 26031929
Cochrane Database Syst Rev. 2013 May 31;(5):CD000165
pubmed: 23728631
Addiction. 2012 Oct;107(10):1878-82
pubmed: 22551065
BMJ. 2013 Aug 19;347:f4921
pubmed: 23963106
Addiction. 2008 Feb;103(2):294-304
pubmed: 17995993
Am J Prev Med. 2008 Aug;35(2):158-76
pubmed: 18617085

Auteurs

Sabrina Kastaun (S)

Institute of General Practice, Addiction Research and Clinical Epidemiology Unit, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Werdener Str. 4, 40227, Düsseldorf, Germany. Sabrina.Kastaun@med.uni-duesseldorf.de.

Verena Leve (V)

Institute of General Practice, Addiction Research and Clinical Epidemiology Unit, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Werdener Str. 4, 40227, Düsseldorf, Germany.

Jaqueline Hildebrandt (J)

Institute of General Practice, Addiction Research and Clinical Epidemiology Unit, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Werdener Str. 4, 40227, Düsseldorf, Germany.

Christian Funke (C)

Institute of General Practice, Addiction Research and Clinical Epidemiology Unit, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Werdener Str. 4, 40227, Düsseldorf, Germany.

Stephanie Becker (S)

Institute of General Practice, Addiction Research and Clinical Epidemiology Unit, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Werdener Str. 4, 40227, Düsseldorf, Germany.

Diana Lubisch (D)

Institute of General Practice, Addiction Research and Clinical Epidemiology Unit, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Werdener Str. 4, 40227, Düsseldorf, Germany.

Wolfgang Viechtbauer (W)

Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, Netherlands.

Olaf Reddemann (O)

Institute of General Practice, Addiction Research and Clinical Epidemiology Unit, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Werdener Str. 4, 40227, Düsseldorf, Germany.

Linn Hempel (L)

Clinical Institute of Psychosomatic Medicine and Psychotherapy, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.

Hayden McRobbie (H)

Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.
The Dragon Institute for Innovation, Auckland, New Zealand.

Tobias Raupach (T)

Department of Cardiology and Pneumology, University Medical Centre Göttingen, Göttingen, Germany.
Research Department of Behavioural Science and Health, Institute of Epidemiology and Health Care, University College London, London, UK.

Robert West (R)

Research Department of Behavioural Science and Health, Institute of Epidemiology and Health Care, University College London, London, UK.

Daniel Kotz (D)

Institute of General Practice, Addiction Research and Clinical Epidemiology Unit, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Werdener Str. 4, 40227, Düsseldorf, Germany.
Research Department of Behavioural Science and Health, Institute of Epidemiology and Health Care, University College London, London, UK.
Department of Family Medicine, CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH